Trial: Higher Bupivacaine Doses Do Not Improve Nerve Block Headache Relief

Acute, severe headaches are a frequent and challenging presentation in the emergency department, often requiring aggressive multimodal treatment [1]. In recent years, the transnasal sphenopalatine ganglion block (a technique delivering local anesthetic to a major facial nerve cluster linked to trigeminal pain pathways) has emerged as a promising, minimally invasive alternative to systemic medications for both primary headaches and post-dural puncture headaches [2, 3, 4]. By interrupting pain signals directly at the ganglion, clinicians can often achieve rapid analgesia while avoiding the side effects of opioids or the need for invasive epidural blood patches [5, 4]. Despite the growing popularity of this bedside procedure, standardized dosing protocols remain poorly defined, leaving physicians to guess whether larger volumes of anesthetic yield better results [4]. A new randomized clinical trial now offers fresh insights into the optimal dosing strategy for achieving sustained headache relief in the acute care setting [6].